SCYNEXIS, Inc. (SCYX)

$1.87

+0.01 (+0.54%)
Rating:
Recommendation:
Neutral
Symbol SCYX
Price $1.87
Beta 2.059
Volume Avg. 0.23M
Market Cap 60.924M
Shares () -
52 Week Range 1.7-8.1
1y Target Est -
DCF Unlevered SCYX DCF ->
DCF Levered SCYX LDCF ->
ROE -89.64% Strong Sell
ROA -30.15% Strong Sell
Operating Margin -
Debt / Equity 186.59% Buy
P/E -
P/B 1.54 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest SCYX news


Dr. Marco Taglietti
Healthcare
Drug Manufacturers—Specialty & Generic
NASDAQ Global Market

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.